Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML)

Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML)

CML Monitor Provides Innovative Method for Tracking Symptoms and Monitoring BCR-ABL Lab Test Results for Physicians and People Living with CML

NEW YORK--(BUSINESS WIRE)-- Medivo Inc., a health monitoring platform that regularly connects doctors, consumers and clinical labs, today announced the launch of CML Monitor, a free mobile app for people living with chronic myelogenous (or myeloid) leukemia (CML).


This new app simplifies daily life for people living with CML by providing them an innovative way to easily and accurately track BCR-ABL laboratory testing results and symptoms while delivering reports to their physicians for optimizing treatment.

CML Monitor is available for iOS and Android devices. Watch a video or download the app here. (www.medivo.com/cml/)

The app provides testing reminders and also enables people living with CML to connect with participating physicians, who receive regular patient updates to make better-informed treatment decisions. Additional features include noting questions for doctors, documenting hospitalizations, creating custom symptoms and socializing with others living with CML.

"Monitoring disease response to therapy is one of the key requests of people living with CML," said Dr. Jason Bhan, EVP and Co-Founder of Medivo. "With this new app, Medivo is able to help consumers track their progress and also help physicians more closely monitor response to therapy and changes in condition symptoms."

The new CML Monitor app builds upon the success Medivo has achieved with its popular GI Monitor app, the leading mobile disease monitoring application for people living with IBD, and HAE Monitor app, which allows people with hereditary angioedema to easily track symptoms and deliver reports to their physicians.

CML, also known as chronic myelogenous leukemia, is a type of cancer that begins in the blood-forming cells of the bone marrow. It can move into the blood and subsequently spread to other parts of the body. The term "myelogenous" in CML refers to the type of cells affected by this cancer, which typically affects older adults.

About Medivo

Medivo is the emerging, cloud-based, health monitoring platform that connects doctors, consumers and clinical labs. Its unique access to clinical data and advanced analytics simplifies and improves health interactions. Medivo makes it easy to access lab tests, measure and track health information. All services—including mobile tools and simple explanations of lab results—are free for physicians and consumers. New York City-based Medivo is venture-backed and its key investor is Safeguard Scientifics, Inc. For more information, visit our website at www.medivo.com or download our apps for iPhone and Android.



Medivo Inc.
Mark Tosh
Director of Corporate Communications
347-862-9225
mtosh@medivo.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML) originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Basics of Diversification

Learn one of the fundamental concepts of building a portfolio.

View Course »

Managing your Portfolio

Keeping your portfolio and financial life fit!

View Course »

Add a Comment

*0 / 3000 Character Maximum